Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Gain Therapeutics (GANX) Research & Development (2020 - 2025)

Gain Therapeutics has reported Research & Development over the past 6 years, most recently at $2.3 million for Q4 2025.

  • Quarterly results put Research & Development at $2.3 million for Q4 2025, up 91.65% from a year ago — trailing twelve months through Dec 2025 was $10.2 million (down 5.36% YoY), and the annual figure for FY2025 was $10.2 million, down 5.36%.
  • Research & Development for Q4 2025 was $2.3 million at Gain Therapeutics, down from $2.8 million in the prior quarter.
  • Over the last five years, Research & Development for GANX hit a ceiling of $4.4 million in Q2 2024 and a floor of $1.2 million in Q4 2024.
  • Median Research & Development over the past 5 years was $2.4 million (2023), compared with a mean of $2.4 million.
  • Biggest five-year swings in Research & Development: surged 479.4% in 2021 and later crashed 48.41% in 2024.
  • Gain Therapeutics' Research & Development stood at $1.5 million in 2021, then skyrocketed by 54.42% to $2.3 million in 2022, then increased by 4.4% to $2.4 million in 2023, then crashed by 48.41% to $1.2 million in 2024, then surged by 91.65% to $2.3 million in 2025.
  • The last three reported values for Research & Development were $2.3 million (Q4 2025), $2.8 million (Q3 2025), and $2.8 million (Q2 2025) per Business Quant data.